Arcus Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
All right. Well, thanks so much, everyone, for joining us. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley, and we're very pleased to have Arcus with us this afternoon. We have Terry Rosen, the company's CEO; and Jen Jarrett, the company's COO. Thank you both for being here.
Before we get started, please see Morgan Stanley's research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Questions & Answers
Well, again, thank you both for being here. I thought one place we'd start would be just high-level, obviously, the Gilead collaboration has been very important for the company as we think about what it's allowed you to do in terms of kind of parallel process opportunities, strength of balance
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |